Reactome | ERBB2 KD mutants bind TKIs

Schema > Reaction > Entries

ERBB2 KD mutants bind TKIs Show undefined attributes

authored	[InstanceEdit:9656339] Orlic-Milacic, Marija, 2019-07-31
category	binding
compartment	[Compartment:70101] cytosol [Compartment:876] plasma membrane
created	[InstanceEdit:9665122] Orlic-Milacic, Marija, 2019-10-30
crossReference	[DatabaseIdentifier:12020745] Mondo:0004992
dbId	9665121
disease	[Disease:1500689] cancer
displayName	ERBB2 KD mutants bind TKIs
edited	[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
eventOf	[Pathway:R-HSA-9664565] Signaling by ERBB2 KD Mutants - Homo sapiens
input	[Complex:R-HSA-9665141] ERBB2 KD mutants (TKI sensitive):ERBIN:HSP90:CDC37 [plasma membrane] [DefinedSet:R-ALL-9665127] TKIs (ERBB2) [cytosol]
isChimeric	false
isInDisease	true
isInferred	false
literatureReference	[LiteratureReference:9646435] Activating HER2 mutations in HER2 gene amplification negative breast cancer [LiteratureReference:9649397] Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib [LiteratureReference:9649445] High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2 [LiteratureReference:9646776] EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation [LiteratureReference:9647026] An Acquired HER2^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer [LiteratureReference:9646962] Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity [LiteratureReference:9646964] Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor [LiteratureReference:9650832] Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations [LiteratureReference:9650849] Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations [LiteratureReference:9665657] The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
maxDepth	1
modified	[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	ERBB2 KD mutants bind TKIs
output	[Complex:R-HSA-9665144] ERBB2 KD mutants:TKIs:ERBIN:HSP90:CDC37 [plasma membrane]
releaseDate	2019-12-10
reviewStatus	[ReviewStatus:9821382] five stars
reviewed	[InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16
schemaClass	Reaction
species	[Species:48887] Homo sapiens
stId	R-HSA-9665121
summation	[Summation:9665160] Sensitivity to different tyrosine kinase inhibitors varies a...
updateTrackers	[UpdateTracker:9835730] Update Tracker - [Reaction:9665121] ERBB2 KD mutants bind TKIs - v85:[modifyText]

Referrals

(updatedInstance)	[UpdateTracker:9835730] Update Tracker - [Reaction:9665121] ERBB2 KD mutants bind TKIs - v85:[modifyText]
(hasEvent)	[Pathway:R-HSA-9664565] Signaling by ERBB2 KD Mutants

Cite Us!